DOCSLIB.ORG

Meeting Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Meeting Program (5-13-11) 73rd CPDD 2011 Meet COVER-1_Layout 1 5/17/11 9:13 AM Page 1 P R O G R A M 73rd Annual Scientific Meeting 2011 Meeting INRC The College on Problems International Narcotics of Drug Dependence Research Conference June 18-23, 2011 June 21-25, 2011 The Westin Diplomat Hollywood, Florida CPDD Board of Directors Anna Rose Childress, PhD, President Linda B. Cottler, PhD, MPH Linda J. Porrino, PhD, Past-President Richard De La Garza, II, PhD Scott E. Lukas, PhD, President-Elect David A. Fiellin, MD Martin W. Adler, PhD, Executive Officer Leonard L. Howell, PhD Sharon L. Walsh, PhD, Interim Treasurer Mary Jeanne Kreek, MD Patrick M. Beardsley, PhD Geoffrey K. Mumford, PhD Lawrence S. Brown, MD, MPH Edward V. Nunes, MD Theodore J. Cicero, PhD Richard A. Rawson, PhD Sandra D. Comer, PhD Roger D. Spealman, PhD Andrew Coop, PhD Eric C. Strain, MD CPDD Scientific Program Committee Sandra D. Comer, PhD, Chair Leonard Howell, PhD Sari Izenwasser, PhD, Past Chair Cynthia Kuhn, PhD Martin W. Adler, PhD, ex officio Michelle R. Lofwall, MD Ellen B. Geller, MA, ex officio Lance R. McMahon, PhD Adam Bisaga, MD Janet L. Neisewander, PhD Alan J. Budney, PhD Jennifer W. Tidey, PhD Howard D. Chilcoat, ScD Ellen M. Unterwald, PhD Rebecca Craft, PhD Elise Weerts, PhD Patrick M. Flynn, PhD INRC Program Committee INRC Executive Committee Co-Chairs John Traynor, PhD, President Sari Izenwasser, PhD (USA) Lakshmi Devi, PhD, Past-President Ellen Unterwald, PhD (USA) Jean Bidlack, PhD, Treasurer Eric Simon, PhD, Past-Treasurer Members Craig Stevens, PhD, Information John Traynor, PhD (USA) Kelly Standifer, PhD (USA) Members Brigitte Kieffer, PhD (France) Lih-Chu Chiou, PhD (Taiwan) Craig Stevens, PhD (USA) Mark Connor, PhD (Australia) Steven Husbands, PhD (UK) Louis Gendron, PhD (Canada) Susan Ingram, PhD (USA) Local Organizing Committee Shiro Kishioka, MD, PhD (Japan) Sari Izenwasser, PhD Ian Kitchen, PhD (UK) Jean Bidlack, PhD, INRC Treasurer Graeme Milligan, PhD (UK) Laura Bohn, PhD Ingrid Nylander, PhD (Sweden) Amy Starosciak, PhD Ellen Unterwald, PhD (USA) Dean Wade, BA PRE-MEETING SATELLITES NIDA: Fundamental Genetics in Drug Abuse and Addiction Diplomat 1-2 Chaired by Minda R. Lynch and Joni L. Rutter June 17 International Women’s Fourth Meeting and Conference: Great Hall 1-2 Drug Use, Abuse, and Dependence in Young Women: June 17 Promising Interventions and Treatments Chaired by Frances E. Ashe-Goins and Wendee Wechsberg The 15th Annual NIDA International Forum: Building Room 212-213 International Collaborative Research on Drug Abuse June 17 – 18 Chaired by Steven Gust Addiction Studies Program for Journalists (ASPJ) Diplomat 4-5 (By Invitation Only) June 17 - 18 The International Study Group Investigating Atlantic 3 Drugs as Reinforcers (ISGIDAR) June 18 Chaired by S. Barak Caine 11 th Annual Meeting Center for Substance Abuse Atlantic 1 Treatment (CSAT) June 18 CPDD/INRC REGISTRATION 3rd Floor Registration Conference Center Saturday, June 18 1:00 PM - 5:00 PM Sunday, June 19 7:30 AM - 11:30 AM 1:00 PM - 5:00 PM Monday, June 20 7:30 AM - 11:30 AM 1:00 PM - 5:00 PM Tuesday, June 21 7:30 AM - 11:30 AM 1:00 PM - 5:00 PM Wednesday, June 22 8:00 AM - 11:30 AM 2:00 PM - 6:00 PM Thursday, June 23 7:30 AM - 11:30 AM 2:30 PM - 5:00 PM Friday, June 24 8:30 AM - 12:00 Noon CPDD OPENING RECEPTION (Cash Bar) GREAT HALL 1-3 Saturday, June 18 7:00 PM - 9:00 PM (Pre-registrants can pick up badges only) Sunday, June 19, 2011 CSAT Travel Awards Breakfast Room 214 (By Invitation Only) 7:30 - 8:30 AM Plenary Session Atlantic Ballroom 8:30 - 10:45 AM 8:30 Welcome, CPDD President Anna Rose Childress In Memoriam 8:40 Presentation of the Marian W. Fischman Award to Bertha K. Madras Introduction by Mary Jeanne Kreek and Gregory Miller 8:45 Marian W. Fischman Award Lecture: Public Health and Drug Policy- Challenges for Neuroscience Bertha K. Madras, Harvard Medical School New England Regional Primate Research Center, Southborough, MA 9:30 Presentation of the CPDD/NIDA Media Award to Justin Hunt Introduction by Marc Kaufman 9:35 Presentation of the J. Michael Morrison Award to Steven W. Gust Introduction by Robert Balster 9:40 Presentation of the Joseph Cochin Young Investigator Award to Thomas Prisinzano Introduction by Kenner Rice 9:45 (Posthumous) Presentation of the Mentorship Award to Stephen G. Holtzman Introduction by Heather Kimmel 9:50 Presentation of the Nathan B. Eddy Award to Michael J. Kuhar Introduction by F. Ivy Carroll 9:55 Nathan B. Eddy Award Lecture: Uncensored Reflections on a Research Career: MUs, DATs, CARTs and Beyond Michael J. Kuhar, Yerkes National Primate Center of Emory University, Atlanta, GA Public Policy Forum Atlantic Ballroom 11:00 AM - 1:00 PM Chairs: Martin Y. Iguchi and William Dewey Update from the Hill and Friends of NIDA William Dewey, Virginia Commonwealth University, Richmond, VA Punishment can work: A report on Hawaii’s Project HOPE Angela Hawken, Pepperdine University, Malibu, CA Creation of a substance use and abuse institute Susan Weiss, David Shurtleff, NIDA, Bethesda, MD BADGES MUST BE WORN FOR ALL SESSIONS AND SOCIAL EVENTS 2 Sunday, June 19, 2011 Late-Breaking Research News Regency 1 1:00 – 2:00 PM Chair: Sandra Comer 1:00 A randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents: Main findings K.M. Gray, M.J. Carpenter, N.L. Baker, S.M. DeSantis, A.L. McRae-Clark, K.T. Brady, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 1:05 Drugs of abuse enhance HIV-1 infectivity in dendritic cells by suppressing miR-155 and 20a J. Napuri, Z.M. Saiyed, N. Gandhi, A.Yndart, M. Agudelo, V.B. Pichili, T. Samikkannu, M.P.N Nair, Institute of NeuroImmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 1:10 Depot-naltrexone treatment modulates brain fMRI response to visual cues in heroin-dependent patients D.D. Langleben, K. Ruparel, J.W. Loughead, E. Busch, J. Cornish, A.R. Childress, C.P. O’Brien, University of Pennsylvania School of Medicine and the Philadelphia VA Medical Center, Philadelphia, PA 1:15 Zolpidem enhances idling of the brain: Upregulation of resting state network activity S.C. Licata, S.B. Lowen, L.D. Nickerson, G. H. Trksak, R.R MacLean, S.E. Lukas, Behavioral Psychopharmacology Research Laboratory and Brain Imaging Center, McLean Hospital/Harvard Medical School, Belmont, MA 1:20 Cav1.2 L-type Ca2+ channels mediate cocaine-induced plasticity in the nucleus accumbens, a long-term adaptation dependent on ventral tegmental area Cav1.3 channels K. Schierberl, J. Hao, C. Inturrisi and A. Rajadhyaksha, Weill Cornell Graduated School of Biomedical Sciences, New York, NY 1:25 Subregion specific striatal activity during reward and disappointment R. Salas, P. Baldwin, P.R. Montague, R. De La Garza, II, Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX, Department of Neuroscience, Baylor College of Medicine, Houston, TX, Virginia Tech Carillion Institute, Roanoke, VA, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 3 Sunday, June 19, 2011 1:30 Dopamine D1 receptor antagonism in the orbitofrontal cortex prevents drug context-induced cocaine-seeking behavior in rats H.C. Lasseter, X. Xie, A.M. Wells, AR. Newsome, A. Reittinger, R.A. Fuchs, Department of Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC 1:35 The effects of oral naltrexone on oral d-amphetamine and smoked cocaine in humans P.A. Saccone, S.D. Comer, P. Roux, J.D. Jones, Z.D. Cooper, S.K. Vosburg, M.A. Sullivan, E. Rubin, J.M. Manubay, S. Mogali, M. Haney, R.W. Foltin, Department of Psychiatry, Division on Substance Abuse, Columbia University and NYSPI, New York, NY 1:40 Age-specific risk of starting to engage in extra-medical use of opioid analgesic medicines: United States, 2004-2008 E.A. Meier, J.P. Troost, J.C. Anthony, Department of Epidemiology, Michigan State University, East Lansing, MI 1:45 High prevalence of prescription opioid use preceding heroin use in three west coast cities R.A. Pollini, C. Banta-Green, L. Jenkins, E. Teshale, R. Garfein, School of Medicine, University of California San Diego, La Jolla, CA, Alcohol and Drug Abuse Institute, University of Washington, Seattle, WA, Multnomah County Health Department, Portland, OR, Centers for Disease Control and Prevention, Atlanta, GA 1:50 Menthol preference among smokers: Association with TRPA1 variants G.R. Uhl, D. Walther, C. Johnson, F.M. Behm, J.E. Rose, Molecular Neurobiology, NIH IRP (NIDA) Baltimore MD, Center for Nicotine and Smoking Cessation Research, Duke University, Durham NC 1:55 ADHD symptoms predict affective functioning in smokers with and without PTSD J.T. Mitchell, E.E. Van Voorhees, F.J. McClernon, S.H. Kollins, P.S. Calhoun, J.C. Beckham, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, Veterans Affairs Medical Center, Durham, NC, Mid-Atlantic Mental Illness Research Education and Clinical Center, Durham, NC, VA Center for Health Services Research in Primary Care, Durham, NC 4 Sunday, June 19, 2011 Symposium I Regency 1 2:15 - 4:15 PM PRENATAL COCAINE EXPOSURE IN ANIMALS AND HUMANS: SEX DIFFERENCES ACROSS THE LIFESPAN Chairs: Cora Lee Wetherington and Samia D. Noursi 2:15 Differential effects of prenatal cocaine and environment on reward in male and female adolescent rats Diana Dow-Edwards, State University of New York, Downstate Medical Center, Brooklyn, NY 2:45 Long-term behavioral and neuropharmacological consequences to prenatal cocaine exposure in male and female rhesus monkeys Michael A.
Load more

Recommended publications
  • 2015 Annual Conference & Hill
    LEARN CONNECT ADVOCATE SUCCEED Welcome to Washington, D.C. and the 2015 Annual Conference & Hill Day October 9 – 13 Washington, D.C. Bethesda North Marriott Hotel & Conference Center MATHISWORKS & SEAMARTINI | PHOTOSPIN.COM Visit booth 105 vivitrol.com/hcp VIVITROL is a registered trademark of Alkermes, Inc. ©2014 Alkermes, Inc. All rights reserved VIV-001684 Printed in U.S.A. vivitrol.com CONTENTS WELCOME Schedule at a Glance 4 Welcome to the NAADAC Annual Conference & Hill Day! As NAADAC President, I, and the Mid-Atlantic Affiliates, welcome you to the 2015 NAADAC Annual Business Meetings 5 Conference & Hill Day, Learn Connect Advocate Succeed. We are thrilled to be hold ing our General Information 7 conference in Washington, D.C. and combining our Advocacy and Annual Conferences into this special event. Download the 2015 Conference App 7 This conference not only includes a strong lineup of keynote and plenary speakers, but also a mul- Continuing Education 8 titude of workshops with the latest information on the trends and issues that impact all addiction- Thank You to All of Our Sponsors, 9 focused professionals. In addition, on Tuesday, October 13, 2015, NAADAC members and other Exhibitors, and Partners addiction-focused professionals from across the country will participate in a special Advocacy in Action briefing and then convene on Capitol Hill to meet with their congressional representatives Daily Schedule 10 to advocate for the addiction profession. Presenter Biographies 27 The conference isn’t all about learning, however. It is also about networking and having fun. As in The Exhibitors 39 the past, we will be recognizing contributions to the addiction profession and outstanding achieve- ment efforts at our awards luncheon.
    [Show full text]
  • Modulation of the Mu and Kappa Opioid Axis for Treatment of Chronic Pruritus
    Modulation of the Mu and Kappa Opioid Axis for the Treatment of Chronic Pruritus Sarina Elmariah, MD, PhD1, Sarah Chisolm, MD2, Thomas Sciascia, MD3, Shawn G. Kwatra, MD4 1Massachusetts General Hospital, Boston, MA, USA; 2Emory University Department of Dermatology, Atlanta, GA, USA; VA VISN 7, USA; 3Trevi Therapeutics, New Haven, CT, USA; 4Johns Hopkins University School of Medicine, Baltimore, MD, USA Introduction Results Conclusions • Conditions such as uremic pruritus (UP) and prurigo nodularis • In the United States, opioid receptor–targeting agents have been used off-label to Figure 4. Change in VAS Scores From Baseline (Preobservation Period) to Last 7 – In a patient subgroup with severe UP (n=179), sleep disruption attributed to • These data suggest that agents that modulate underlying are characterized by chronic pruritus, which negatively impacts treat chronic itch19 Days of Treatment With KOR Agonist Nalfurafine vs Placebo for Uremic Pruritus21 itching improved significantly vs placebo (P=0.006) neurologic components of pruritus through µ-antagonism quality of life (QoL), sleep, and mood1-7 and/or κ-agonism are effective and safe options for the • Several agents that target MORs and KORs are being used off-label or are in clinical alfurafine 2.5 µg alfurafine 5 µg Placeo – The most common reason for discontinuing treatment was gastrointestinal side n112 n114 n111 treatment of chronic pruritus • Opioid receptors and their endogenous ligands are involved in development for the treatment of chronic itch associated with various disease states 0 effects (eg, nausea, vomiting) during titration the regulation of itch, with activation of mu (µ) opioid receptors (Figure 2) These agents have low abuse potential and generally appear well Figure 5.
    [Show full text]
  • Evaluation of Antinociceptive Effects of Chitosan-Coated Liposomes Entrapping the Selective Kappa Opioid Receptor Agonist U50,488 in Mice
    medicina Article Evaluation of Antinociceptive Effects of Chitosan-Coated Liposomes Entrapping the Selective Kappa Opioid Receptor Agonist U50,488 in Mice Liliana Mititelu Tartau 1, Maria Bogdan 2,* , Beatrice Rozalina Buca 1, Ana Maria Pauna 1, Cosmin Gabriel Tartau 1, Lorena Anda Dijmarescu 3 and Eliza Gratiela Popa 4 1 Department of Pharmacology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania; liliana.tartau@umfiasi.ro (L.M.T.); beatrice-rozalina.buca@umfiasi.ro (B.R.B.); ana-maria-raluca-d-pauna@umfiasi.ro (A.M.P.); [email protected]fiasi.ro (C.G.T.) 2 Department of Pharmacology, Faculty of Pharmacy, University of Medicine and Pharmacy, 200349 Craiova, Romania 3 Department of Obstetrics-Gynecology, Faculty of Medicine, University of Medicine and Pharmacy, 200349 Craiova, Romania; [email protected] 4 Department of Pharmaceutical Technology, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania; eliza.popa@umfiasi.ro * Correspondence: [email protected] Abstract: Background and Objectives: The selective kappa opioid receptor agonist U50,488 was reported to have analgesic, cough suppressant, diuretic and other beneficial properties. The aim of our study was to analyze the effects of some original chitosan-coated liposomes entrapping U50,488 in somatic and visceral nociceptive sensitivity in mice. Materials and Methods: The influence on the somatic pain was assessed using a tail flick test by counting the tail reactivity to thermal noxious stimulation. Citation: Mititelu Tartau, L.; Bogdan, The nociceptive visceral estimation was performed using the writhing test in order to evaluate the M.; Buca, B.R.; Pauna, A.M.; Tartau, behavioral manifestations occurring as a reaction to the chemical noxious peritoneal irritation with C.G.; Dijmarescu, L.A.; Popa, E.G.
    [Show full text]
  • Chronic Kidney Disease-Associated Pruritus
    toxins Review Chronic Kidney Disease-Associated Pruritus Puneet Agarwal 1 , Vinita Garg 2, Priyanka Karagaiah 3, Jacek C. Szepietowski 4 , Stephan Grabbe 5 and Mohamad Goldust 5,* 1 Department of Dermatology, SMS Medical College and Hospital, Jaipur 302004, Rajasthan, India; [email protected] 2 Consultant Nephrologist, MetroMas Hospital, Jaipur 302020, Rajasthan, India; [email protected] 3 Department of Dermatology, Bangalore Medical College and Research Institute, Bangalore 560002, Karnataka, India; [email protected] 4 Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-367 Wroclaw, Poland; [email protected] 5 Department of Dermatology, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany; [email protected] * Correspondence: [email protected] Abstract: Pruritus is a distressing condition associated with end-stage renal disease (ESRD), advanced chronic kidney disease (CKD), as well as maintenance dialysis and adversely affects the quality of life (QOL) of these patients. It has been reported to range from 20% to as high as 90%. The mechanism of CKD-associated pruritus (CKD-aP) has not been clearly identified, and many theories have been proposed to explain it. Many risk factors have been found to be associated with CKD-aP. The pruritus in CKD presents with diverse clinical features, and there are no set features to diagnose it.The patients with CKD-aP are mainly treated by nephrologists, primary care doctors, and dermatologists. Many treatments have been tried but nothing has been effective. The search of literature included peer- reviewed articles, including clinical trials and scientific reviews. Literature was identified through March 2021, and references of respective articles and only articles published in the English language were included.
    [Show full text]
  • Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: a Literature Review
    Included in the theme issue: ATOPIC DERMATITIS, URTICARIA AND ITCH Acta Derm Venereol 2012; 92: 555–560 Acta Derm Venereol 2012; 92: 449–581 REVIEW ARTICLE Systemic Kappa Opioid Receptor Agonists in the Treatment of Chronic Pruritus: A Literature Review Ngoc Quan PHAN1, Tobias LOTTS1, Attila Antal2, Jeffrey D. BERNHARD3 and Sonja STÄNDER1 1Competence Center Chronic Pruritus, Department of Dermatology, University Hospital Münster, Münster, 2Department of Dermatology and Allergology Ludwig-Maximilians-University, München, Germany, and 3Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachu- setts, USA Chronic pruritus is frequently refractory to currently studies antipruritic effects in antihistamine-resistant and available treatments. Studies suggest that pruritus may antihistamine-sensitive pruritus in animals and humans arise from an imbalance of the mu- and kappa-opioid re- (3, 4). Given that an imbalance of the endogenous opioid ceptor system activity in either the skin or the central system has been considered as a pathomechanism in nervous system. Stimulation of kappa-opioid receptors uraemic pruritus, antipruritic effects of KOR agonists by their agonists inhibits pruritus in both animals and have been investigated in randomized controlled trials humans. The antipruritic effect of kappa-opioid recep- (RCT) in this indication (5–8). The major advantage of tors agonists can currently be assumed to be related to the KOR agonists over MOR antagonists seems to be their binding to kappa-opioid receptors on keratinocy- the fewer rates of up-to-date reported adverse events. tes and cutaneous and/or central itch neurones. To date, MOR antagonists show a high rate of troublesome side- several case reports and 2 controlled trials have de- effects (1), hampering their application mainly in elderly monstrated a beneficial effect of systemic kappa-opioid patients.
    [Show full text]
  • The 6Th Annual
    JULY 15-18, 2018 OMNI AMELIA ISLAND PLANTATION RESORT AMELIA ISLAND, FLORIDA Onsite Program Supported by The 6th Annual Recovery Experience COREClinical Overview of the Hosted by In Collaboration with Scan the QR Code below to download our app • Earn up to 25 HOURS of Continuing Education • Choose from 30 challenging workshops One call is all it takes. We are committed to working with you to get your clients into treatment as quickly and easily as possible. From admissions paperwork to transportation, our consultants will manage the entire process for you, keeping you informed every step of the way. Our full spectrum of addiction treatment services, emphasis on dual-diagnosis, and multitude of locations nationwide mean that we have a program to fit the unique needs of each of your clients. American Addiction Centers is a leading provider of inpatient substance abuse treatment services. We treat adults who are struggling with drug addiction, alcohol addiction, and co-occurring mental/behavioral health issues. With coast-to-coast facilities and caring, highly-seasoned professionals, American Addiction Centers is your ideal treatment partner. One call is all it takes. 866.537.6237 Learn More About How We Can Help. CALL 866.537.6237 Consultants Available 24/7 americanaddictioncenters.org americanaddictioncenters.org One call is all it takes. We are committed to working with you to get your clients into treatment as quickly and easily as possible. From admissions paperwork to transportation, our consultants will manage the entire process for you, keeping you informed every step of the way. Our full spectrum of addiction treatment services, emphasis on dual-diagnosis, and multitude of locations nationwide mean that we have a program to fit the unique needs of each of your clients.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al
    US 20110245287A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday et al. (43) Pub. Date: Oct. 6, 2011 (54) HYBRD OPOD COMPOUNDS AND Publication Classification COMPOSITIONS (51) Int. Cl. A6II 3/4748 (2006.01) C07D 489/02 (2006.01) (76) Inventors: John W. Holaday, Bethesda, MD A6IP 25/04 (2006.01) (US); Philip Magistro, Randolph, (52) U.S. Cl. ........................................... 514/282:546/45 NJ (US) (57) ABSTRACT Disclosed are hybrid opioid compounds, mixed opioid salts, (21) Appl. No.: 13/024,298 compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particu larly, in one aspect the hybrid opioid compound includes at (22) Filed: Feb. 9, 2011 least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different Related U.S. Application Data opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical composi (60) Provisional application No. 61/302,657, filed on Feb. tions, as well as to methods of treating pain in humans using 9, 2010. the hybrid compounds and mixed opioid salts. Patent Application Publication Oct. 6, 2011 Sheet 1 of 3 US 2011/0245287 A1 Oral antinociception of morphine, oxycodone and prodrug combinations in CD1 mice s Tigkg -- Morphine (2.80 mg/kg (1.95 - 4.02, 30' peak time -- (Oxycodone (1.93 mg/kg (1.33 - 2,65)) 30 peak time -- Oxy. Mor (1:1) (4.84 mg/kg (3.60 - 8.50) 60 peak tire --MLN 2-3 peak, effect at a hors 24% with closes at 2.5 art to rigg - D - MLN 2-45 (6.60 mg/kg (5.12 - 8.51)} 60 peak time Figure 1.
    [Show full text]
  • WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/485 (2006.01) A61P 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US20 12/024482 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, ' February 2012 (09.02.2012) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 13/024,298 9 February 201 1 (09.02.201 1) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): QRX- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, PHARMA LTD.
    [Show full text]
  • Confirmation Hearing on the Nomination of John P
    S. HRG. 107–632 CONFIRMATION HEARING ON THE NOMINATION OF JOHN P. WALTERS TO BE DIRECTOR OF THE OFFICE OF NATIONAL DRUG CONTROL POLICY HEARING BEFORE THE COMMITTEE ON THE JUDICIARY UNITED STATES SENATE ONE HUNDRED SEVENTH CONGRESS FIRST SESSION OCTOBER 10, 2001 Serial No. J–107–42 Printed for the use of the Committee on the Judiciary ( U.S. GOVERNMENT PRINTING OFFICE 81–443 PDF WASHINGTON : 2002 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2250 Mail: Stop SSOP, Washington, DC 20402–0001 VerDate Feb 1 2002 13:39 Sep 13, 2002 Jkt 000000 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 C:\HEARINGS\81443.TXT SJUD4 PsN: CMORC COMMITTEE ON THE JUDICIARY PATRICK J. LEAHY, Vermont, Chairman EDWARD M. KENNEDY, Massachusetts ORRIN G. HATCH, Utah JOSEPH R. BIDEN, JR., Delaware STROM THURMOND, South Carolina HERBERT KOHL, Wisconsin CHARLES E. GRASSLEY, Iowa DIANNE FEINSTEIN, California ARLEN SPECTER, Pennsylvania RUSSELL D. FEINGOLD, Wisconsin JON KYL, Arizona CHARLES E. SCHUMER, New York MIKE DEWINE, Ohio RICHARD J. DURBIN, Illinois JEFF SESSIONS, Alabama MARIA CANTWELL, Washington SAM BROWNBACK, Kansas JOHN EDWARDS, North Carolina MITCH MCCONNELL, Kentucky BRUCE A. COHEN, Majority Chief Counsel and Staff Director SHARON PROST, Minority Chief Counsel MAKAN DELRAHIM, Minority Staff Director (II) VerDate Feb 1 2002 13:39 Sep 13, 2002 Jkt 000000 PO 00000 Frm 00002 Fmt 5904 Sfmt 5904 C:\HEARINGS\81443.TXT SJUD4 PsN: CMORC C O N T E N T S STATEMENTS OF COMMITTEE MEMBERS Page Biden, Hon.
    [Show full text]
  • The Battle of the Sexes In
    (AAwDmmm) * THE BATTLE OF THE SEXES IN Hollywoods ¦ i tab war against fat By JANE L. WRIGHT A HANDSOME OOUPLE Mr. and Mrs. Alan Ladd. Sue Ladd says, “/ know how important it is for stars to keep figure perfect .” Lunching recently at the Paramount a few Ayds with me wherever I go to control my trim down, by following his wife’s example. Lita had Commissary, the wife of Hollywood’s romantic appetite." started on the Ayds Plan a short while before. swashbuckler, Alan Ladd, watched curiously as her Many will remember Mrs. Alan Ladd when she “Staying down to your ideal weight is sometimes companion devoured a rich dessert of strawberry was a star in her own right. For ten years, pert and hard until you discover Ayds,” said Rory in an shortcake with whipped cream. pretty Sue Carol was featured in a series of movies. interview. "But I’m convinced two can reduce, lose “Hungry for some?” she was asked. Then she decided to switch careers. Sue gave up film excess pounds easier than one.” “Not at all,” replied Sue Ladd. “Icurb my appe- work to devote her time to being an actor's agent. “Absolutely,”agreed Lita. “You can make it a kind tite, keep my weight down a perfectly safe, natural Then came marriage to Alan and a family of four of game, by competing with one another. Even when way. I eat what I want, only I want less, because I children. one of us needs to lose more pounds than the other, take these.” And she reached into her purse and held In this new role, Sue began to put on weight, until Ayds helps each of us lose just the right amount.” up a caramel candy.
    [Show full text]
  • GUNSMOKE TV CAST and DETAILS Premiered
    GUNSMOKE TV CAST AND DETAILS Premiered: September 10, 1955, on CBS Rating: TV-PG Premise: This landmark adult Western centered on Marshal Matt Dillon of Dodge City. John Wayne turned down the lead, suggesting James Arness (who remained for its entire run). Originating on radio (with William Conrad as Dillon), it moved to TV in September 1955. Its popularity spawned a number of copycats, but none would enjoy the longevity (and few the consistent quality) of this classic. Airing for 20 years, it's TV's longest running prime-time drama (a record that `Law & Order' is currently chasing). Gunsmoke Cast • James Arness : Marshal Matt Dillon • Milburn Stone : Dr. Galen `Doc' Adams • Amanda Blake : Kitty Russell • Dennis Weaver : Chester Goode • Ken Curtis : Festus Haggen • Burt Reynolds : Quint Asper • James Nusser : Louie Pheeters • Charles Seel : Barney Danches • Howard Culver : Howie Culver • Tom Brown : Ed O'Connor • John Harper : Percy Crump • Dabbs Greer : Mr. Jonus • George Selk : Moss Grimmick • Hank Patterson : Hank Miller • Glenn Strange : Sam • Sarah Selby : Ma Smalley • Ted Jordan : Nathan Burke • Roger Ewing : Clayton Thaddeus `Thad' Greenwood • Roy Roberts : Mr. Bodkin • Woody Chamblis : Mr. Lathrop • Buck Taylor : Newly O'Brien • Charles Wagenheim : Halligan • Pat Hingle : Dr. John Chapman • Fran Ryan : Miss Hannah Gunsmoke Credits • Sam Peckinpah : Screenwriter Gunsmoke Directors • Harry Horner : Director Gunsmoke Guest Cast • Aaron Saxon : Basset • Aaron Spelling : Weed Pindle • Abraham Sofaer : Harvey Easter • Adam West : Hall
    [Show full text]
  • New President Says ASAM Has ·-~ ~ "Talent, Energy, Experience" to Mee1t Chal1enges G
    Newsletter 0 f The American Society' of Addictionr, Medicine ' .- ' ; New President Says ASAM Has ·-~ ~ "Talent, Energy, Experience" to Mee1t Chal1enges G. Douglas Talbott, M.D. , FASAM I assume the Presidency of ASAM with hu­ AMA's Physicians Health Committee. I sub­ The Caduceus Foundation also has convened mility, excitement and a sense of exultation. sequently approached Drs. Gitlow and a number of expert meetings on caffeine, Seixas and the basis of the first Kroc Ranch chaired by Dr. Max Schneider. The findings To follow Dr. David Smith's Presidency is unity meeting was established. from these sessionii.were reported at the 1993 by definition a humbling experience. It is Medical-Scientific Conference in a sympo­ also humbling to be elected President of sium on the role of caffeine in addiction ASAM, for this is truly a great and unique treatment. organization. I exult in the richness of this history, and in Nor can I assume the presidency of this or­ the current accomplishments represented by ganization without exultation. I have been the ASAM Patient Placement Criteria un­ with ASAM from the birth of the Southeast­ der the leadership of Dr. David Mee-Lee and ern addiction movement, the California the efforts on tobacco, led by Dr. John Slade. movement, and the New York movement. The New York programs were much older Goals for the Future than the California and Georgia programs, As we look toward the future, I want to but I learned of the New York program dedicate my presidency to the establish­ through the work of Drs. Frank Seixas, ment of residencies in addiction medicine Sheila Blume, Stan Gitlow, and through my in a number of university medical centers.
    [Show full text]